Morgan Stanley’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-28,163
| Closed | -$35K | – | 8331 |
|
|
2022
Q1 | $35K | Buy |
28,163
+14,527
| +107% | +$15.8K | ﹤0.01% | 6880 |
|
|
2021
Q4 | $15K | Sell |
13,636
-2,033
| -13% | -$3.03K | ﹤0.01% | 7335 |
|
|
2021
Q3 | $30K | Sell |
15,669
-835
| -5% | -$1.64K | ﹤0.01% | 6937 |
|
|
2021
Q2 | $39K | Buy |
16,504
+10,957
| +198% | +$26.4K | ﹤0.01% | 6777 |
|
|
2021
Q1 | $15K | Buy |
5,547
+2,139
| +63% | +$6.33K | ﹤0.01% | 6830 |
|
|
2020
Q4 | $8K | Buy |
3,408
+1,300
| +62% | +$2.96K | ﹤0.01% | 6706 |
|
|
2020
Q3 | $5K | Sell |
2,108
-2,534
| -55% | -$6.65K | ﹤0.01% | 6462 |
|
|
2020
Q2 | $10K | Buy |
4,642
+1,769
| +62% | +$4.07K | ﹤0.01% | 6174 |
|
|
2020
Q1 | $5K | Buy |
2,873
+464
| +19% | +$938 | ﹤0.01% | 6249 |
|
|
2019
Q4 | $5K | Buy |
2,409
+2,407
| +120,350% | +$5.71K | ﹤0.01% | 6411 |
|
|
2019
Q3 | $0 | Sell |
2
-6,612
| -100% | -$22.6K | ﹤0.01% | 6957 |
|
|
2019
Q2 | $26K | Buy |
+6,614
| New | +$34.5K | ﹤0.01% | 5850 |
|
|
2019
Q1 | – | Sell |
-21
| Closed | – | – | 6827 |
|
|
2018
Q4 | $0 | Sell |
21
-1
| -5% | -$5 | ﹤0.01% | 6855 |
|
|
2018
Q3 | $0 | Sell |
22
-37,522
| -100% | -$198K | ﹤0.01% | 6912 |
|
|
2018
Q2 | $257K | Buy |
37,544
+14,763
| +65% | +$110K | ﹤0.01% | 5447 |
|
|
2018
Q1 | $191K | Buy |
22,781
+15,426
| +210% | +$128K | ﹤0.01% | 5490 |
|
|
2017
Q4 | $68K | Buy |
7,355
+1,516
| +26% | +$15.2K | ﹤0.01% | 5748 |
|
|
2017
Q3 | $68K | Buy |
5,839
+780
| +15% | +$29.6K | ﹤0.01% | 5689 |
|
|
2017
Q2 | $211K | Buy |
5,059
+3,015
| +148% | +$145K | ﹤0.01% | 5302 |
|
|
2017
Q1 | $99K | Buy |
2,044
+954
| +88% | +$37.3K | ﹤0.01% | 5604 |
|
|
2016
Q4 | $36K | Sell |
1,090
-982
| -47% | -$32.3K | ﹤0.01% | 5840 |
|
|
2016
Q3 | $85K | Sell |
2,072
-787
| -28% | -$30.9K | ﹤0.01% | 5381 |
|
|
2016
Q2 | $94K | Sell |
2,859
-452
| -14% | -$16.6K | ﹤0.01% | 5266 |
|
|
2016
Q1 | $205K | Sell |
3,311
-243
| -7% | -$7.72K | ﹤0.01% | 4961 |
|
|
2015
Q4 | $150K | Sell |
3,554
-22,730
| -86% | -$1.08M | ﹤0.01% | 5220 |
|
|
2015
Q3 | $1.44M | Buy |
26,284
+18,464
| +236% | +$1.83M | ﹤0.01% | 3803 |
|
|
2015
Q2 | $859K | Buy |
7,820
+3,876
| +98% | +$360K | ﹤0.01% | 4323 |
|
|
2015
Q1 | $375K | Buy |
3,944
+3,819
| +3,055% | +$269K | ﹤0.01% | 4835 |
|
|
2014
Q4 | $7K | Sell |
125
-247
| -66% | -$16.9K | ﹤0.01% | 6280 |
|
|
2014
Q3 | $27K | Sell |
372
-91
| -20% | -$9.96K | ﹤0.01% | 5918 |
|
|
2014
Q2 | $70K | Sell |
463
-1,195
| -72% | -$181K | ﹤0.01% | 5643 |
|
|
2014
Q1 | $240K | Buy |
+1,658
| New | +$203K | ﹤0.01% | 5028 |
|
Other funds holding GNCA
Morgan Stanley's GNCA Position: Q2 2022 in Review
Morgan Stanley sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 28,163 shares — an estimated $35K sold.
Morgan Stanley first reported a position in GNCA in Q1 2014 and held it in 32 quarters. The position peaked at $1.44M in Q3 2015. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Morgan Stanley reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Morgan Stanley sold 28,163 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $35K.
- Morgan Stanley first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 32 quarters.
- Morgan Stanley's Genocea Biosciences, Inc. position peaked at $1.44M in Q3 2015.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Morgan Stanley's 13F filing for Q2 2022, filed 15 Aug 2022.